Background
NSCLC, tumor
NON-SMALL CELL LUNG CANCER, TUMOR, SOLID TUMORS, NSCLC
In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolumab.